Immatics NV (IMTX)

Immatics N.V. is a clinical-stage biopharmaceutical company focused on developing T cell redirecting immunotherapies for cancer. The company’s research efforts center on solid tumors and are organized around two main approaches: adoptive cell therapies (ACT) and antibody-like TCR bispecifics. Its pipeline includes Anzu-cel (IMA203), a PRAME-targeted cell therapy in Phase 2, as well as IMA203CD8 and IMA204, both in Phase 1 studies. Immatics is also evaluating Anzu-cel in combination with Moderna’s mRNA-4203 enhancer in a Phase 1 trial. In its TCR bispecific program, the company is advancing IMA401 and IMA402, both in Phase 1a development. Immatics has collaboration agreements with MD Anderson Cancer Center, Celgene Corporation, and Genmab A/S to support the development of multiple T cell- and TCR-based therapies. The company is headquartered in Tübingen, Germany, and its common stock is listed on NASDAQ under the ticker IMTX.

Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.